Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Gemcitabine and taxanes in metastatic breast cancer: a systematic review

Authors Gudena V, Montero AJ, Glück S

Published 5 December 2008 Volume 2008:4(6) Pages 1157—1164

DOI https://doi.org/10.2147/TCRM.S3120

Review by Single-blind

Peer reviewer comments 2

Vinay Gudena, Alberto J Montero, Stefan Glück

Division of Hematology/Oncology, Braman Family Breast Cancer Institute, UMSylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA

Abstract: Incremental advances over the last two decades in the treatment of stage IV metastatic breast cancer (MBC) have resulted in significantly prolonging the average life expectancy. In 2008, the estimated 5-year relative survival rate for MBC is 27% which compares favorably to rates in stage IV lung (3%) and pancreatic cancers (1%). Despite these advances, MBC remains an incurable disease, often associated with many symptoms and a decreased quality of life (QoL). Therefore, therapy goals in the treatment of MBC include prolonging both progression-free survival and overall survival rates, while at the same time improving QoL by palliation of symptoms. Therefore, systemic chemotherapy ideally should not induce unnecessary toxicities. Once chemotherapy is indicated, a number of drugs and regimens are available but only a few offer both palliation of symptoms (responses to therapy) and overall survival benefit. The addition of novel biologic compounds to chemotherapy has been shown in phase III trials to improve all the above mentioned clinical outcomes in MBC. This review will discuss data supporting the use of gemcitabine/taxane combinations in the treatment of MBC.

Keywords: metastatic breast cancer, gemcitabine, taxanes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells

Tahmasebi Mirgani M, Isacchi B, Sadeghizadeh M, Marra F, Bilia AR, Mowla SJ, Najafi F, Babaei E

International Journal of Nanomedicine 2014, 9:403-417

Published Date: 13 January 2014

Adiponectin concentration in the orbital fat of patients with Graves' ophthalmopathy

Soiberman U, Levy R, Leibovitch I

Clinical Ophthalmology 2013, 7:1723-1726

Published Date: 26 August 2013

Once-monthly risedronate for postmenopausal osteoporosis

Kristina Casadei, Carolyn Becker

International Journal of Women's Health 2009, 1:1-9

Published Date: 16 February 2009

Febuxostat in the management of hyperuricemia and chronic gout: a review

Miao Hu, Brian Tomlinson

Therapeutics and Clinical Risk Management 2008, 4:1209-1220

Published Date: 5 December 2008

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis

José Luis Callejas-Rubio, Lourdes López-Pérez, Norberto Ortego-Centeno

Therapeutics and Clinical Risk Management 2008, 4:1305-1313

Published Date: 5 December 2008

A review of the use of adapalene for the treatment of acne vulgaris

Suleyman Piskin, Erol Uzunali

Therapeutics and Clinical Risk Management 2007, 3:621-624

Published Date: 15 September 2007

Tiotropium bromide

David A Lipson

International Journal of Chronic Obstructive Pulmonary Disease 2006, 1:107-114

Published Date: 15 June 2006